Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) for patients with Uveal Melanoma that has metastasized to the liver.

Trial Details

NCT ID

NCT07364474

Phase

Sponsor

Massachusetts General Hospital

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

Melphalan through Percutaneous Hepatic Perfusion

Locations (sample)

Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

Patient has histologically or cytologically confirmed diagnosis of uveal melanoma metastatic to the liver and is determined to be a candidate for p…
The subject has read, signed and dated the Informed Consent Form (ICF), having been advised of the risks and benefits of the trial in a language un…
Age \> 18 years at date of informed consent signature having the ability to comply with the protocol.
Contrast-enhanced cross-sectional imaging of the abdomen (either CT or MRI) obtained within two months prior to study enrollment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →